Related Experiment Videos
Rapamycin in patients with chronic renal allograft dysfunction.
Mai-Szu Wu1, Chiz-Tzung Chang, Cheng-Chieh Hung
1Department of Nephrology, Chang Gung Memorial Hospital, Keelung, Taiwan. mazwu1@adm.cgmh.org.tw
Clinical Transplantation
|March 3, 2005
Summary
Converting from calcineurin inhibitors (CNI) to rapamycin improved kidney transplant function in some patients with chronic allograft dysfunction. This switch showed potential benefits, though some patients experienced adverse effects or graft function decline.
Area of Science:
- Nephrology
- Immunosuppression
- Transplantation
Background:
- Calcineurin inhibitors (CNI) are associated with nephrotoxicity, complicating kidney transplant management.
- Chronic allograft dysfunction is a significant concern in kidney transplant recipients.
- Rapamycin offers an alternative immunosuppressive agent with a different toxicity profile.
Purpose of the Study:
- To investigate the efficacy and safety of converting from CNI to rapamycin in kidney transplant recipients experiencing chronic allograft dysfunction.
- To evaluate the impact of this conversion on allograft function and clinical outcomes.
Main Methods:
- A prospective study involving 16 kidney transplant recipients with chronic allograft dysfunction on CNI-based triple therapy.
- Patients underwent direct conversion from CNI to rapamycin, with observation for 6 months.
- Allograft function, clinical features, and adverse events were assessed pre- and post-conversion.
Main Results:
- 62.5% of patients (10/16) experienced improved graft function after conversion, with a significant average serum creatinine reduction of 27.7%.
- Successful conversion was associated with improvements in anemia and diastolic blood pressure.
- 37.5% of patients (6/16) experienced conversion failure due to graft deterioration or adverse effects; failed conversions were linked to longer post-transplant duration.
Conclusions:
- Conversion from CNI to rapamycin can be beneficial for select kidney transplant recipients with chronic allograft dysfunction.
- Careful patient selection and monitoring are crucial due to potential adverse effects and conversion failures.